- In April 2023, Baxter International Inc., a global healthcare company, announced the expansion of its advanced surgical solutions portfolio by launching a new fibrin sealant under the brand TISSEEL Evolution. This next-generation natural biomedical adhesive enhances hemostasis and tissue sealing capabilities during complex surgeries. The product leverages improved viscosity and application precision, supporting surgeons in achieving better patient outcomes across cardiovascular and gastrointestinal procedures.
- In March 2023, B. Braun Melsungen AG, a leading medical and pharmaceutical device company, introduced Coseal, a synthetic polyethylene glycol-based surgical sealant, into emerging Asia-Pacific markets. The move aligns with B. Braun’s strategic plan to strengthen its footprint in minimally invasive surgeries. Coseal is primarily designed to reduce post-operative complications by preventing adhesions and sealing vascular grafts.
- In March 2023, CryoLife, Inc. (now Artivion, Inc.) announced CE Mark recertification and further distribution expansion of BioGlue® Surgical Adhesive, one of the most widely used synthetic adhesives in cardiovascular surgeries. This development not only complies with the evolving European MDR but also ensures uninterrupted availability of life-saving surgical adhesives across EU markets.
- In February 2023, Ethicon, a subsidiary of Johnson & Johnson MedTech, initiated clinical trials for a novel bioresorbable adhesive derived from natural proteins and polymers. The adhesive is designed to offer a biodegradable alternative to traditional sutures in skin and soft tissue surgeries. Early trial results show promise in reducing healing time and minimizing scarring, addressing a critical need in cosmetic and reconstructive surgeries.
- In January 2023, Cohera Medical, Inc., a developer of absorbable surgical adhesives, announced progress in FDA regulatory submission for its Sylys® Surgical Sealant, a synthetic adhesive designed to reinforce gastrointestinal anastomoses. This development marks a significant step toward commercialization in the U.S., with the potential to reduce post-operative leaks and complications in colorectal procedures.
